EGFL11 Inhibitors

Chemical inhibitors of EGFL11 include a variety of matrix metalloprotease (MMP) inhibitors, which are crucial to the functional inhibition of the protein due to its potential involvement in the extracellular matrix (ECM) remodeling. Marimastat and GM6001, for instance, serve as broad-spectrum MMP inhibitors, targeting the enzymes responsible for processing and degrading components of the ECM, including proteins such as EGFL11. By inhibiting these MMPs, the normal maturation or degradation of EGFL11 is likely impeded, leading to a decrease in its functional activity. Similar in action, PD166793 and Batimastat block various MMPs, with Batimastat also specifically known to inhibit angiogenesis, a process that could be related to the function of EGFL11 if it interacts with the ECM during new blood vessel formation. CP-471474, ARP101, and WAY-170523 also contribute to this MMP inhibition, each targeting specific enzymes like MMP-2 and MMP-13, which are implicated in remodeling the ECM and potentially affecting the functional role of EGFL11.

Further inhibitory effects on EGFL11 come from chemicals like TAPI-0, which blocks the tumor necrosis factor-alpha converting enzyme (TACE), potentially affecting the proteolytic processing of other proteins within the EGFL11 signaling pathways. Ro 32-3555, another MMP inhibitor, specifically targets MMP-9, which can alter ECM composition and signaling, leading to downstream effects on EGFL11 function. ML-3000's inhibition of 5-lipoxygenase and cyclooxygenases can reduce inflammation-associated ECM remodeling, thereby indirectly affecting EGFL11 activity if it is involved in inflammatory processes related to the ECM. Lastly, AG3340, known as Prinomastat, rounds out the group by targeting MMPs to maintain ECM integrity, which can have a stifling effect on the functional activity of EGFL11 if it relies on the dynamic state of the ECM for its activity.